~~<i id='41A39EA37E'><strike id='41A39EA37E'><tt id='41A39EA37E'><pre id='41A39EA37E'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：fashion 2025-09-30 12:56:41 Page View：11

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Why are Kaiser Permanente staff considering a strike?
Next article： United colonoscopy coverage change 'may cost lives,' doctors say

explore

Anesthesiologist group: stop taking Ozempic before surgery

EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

How AI helped researchers track recovery from depression

AdobeResearcherssaythey’vebeenabletomeasurerecoveryfromtreatment-resistantdepressionthroughbrainscan

New air purifier tech could be key to improving indoor air quality

AdobeUntiltheearly20thcentury,Americaregularlyexperiencedbrutallydestructiveurbanfires.Conflagration

New details revealed about Purdue's marketing of OxyContin

MassachusettsAttorneyGeneralMauraHealeyJessicaRinaldi/TheBostonGlobeWhenPurduePharmastartedsellingit